Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-021-06572-4
Abstract: Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors plus chemotherapy have become the standard first line of treatment in patients with advanced non-small-cell lung cancer (NSCLC). However, few studies have explicitly focused on the impact… read more here.
Keywords: plus chemotherapy; inhibitors plus; treatment; weight loss ... See more keywords
Efficacy and safety of CTLA‐4 inhibitors combined with PD‐1 inhibitors or chemotherapy in patients with advanced melanoma
Sign Up to like & getrecommendations! Published in 2019 at "International Immunopharmacology"
DOI: 10.1016/j.intimp.2018.12.034
Abstract: Background: Although immune checkpoint inhibitor monotherapy has demonstrated significant efficacy in advanced melanoma, no study has systematically evaluated the efficacy and safety of the combination regimens. In this study, we conduct a comprehensive meta‐analysis to… read more here.
Keywords: advanced melanoma; inhibitors plus; ctla inhibitors; safety ... See more keywords
PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.958869
Abstract: Background Lenvatinib, regorafenib and anti-programmed cell death protein-1 (PD-1) immunotherapy have shown promising clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure, respectively. However, the combination of the two treatments has not… read more here.
Keywords: advanced hepatocellular; lenvatinib regorafenib; patients advanced; failure ... See more keywords